No Data
Lamb Weston, FedEx, BioNTech, Zscaler, Larimar Trending With Analysts
Larimar Therapeutics Initiated at Overweight by JP Morgan
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9
Express News | Larimar Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $9
Larimar Shareholders Approve Governance and Capital Structure Changes
Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics